Publication: Assessing evidence of interaction between smoking and warfarin: A systematic review and meta-analysis
Issued Date
2011-05-01
Resource Type
ISSN
19313543
00123692
00123692
Other identifier(s)
2-s2.0-79955749858
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Chest. Vol.139, No.5 (2011), 1130-1139
Suggested Citation
Surakit Nathisuwan, Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk, Tatiya Morarai, Thararat Yodting, Nichakorn Piriyachananusorn Assessing evidence of interaction between smoking and warfarin: A systematic review and meta-analysis. Chest. Vol.139, No.5 (2011), 1130-1139. doi:10.1378/chest.10-0777 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/12520
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Assessing evidence of interaction between smoking and warfarin: A systematic review and meta-analysis
Other Contributor(s)
Abstract
Background: Chronic smoking, theoretically, can interfere with warfarin metabolism through enzyme-inducing effects of polycyclic aromatic hydrocarbons. However, clinical evidence of interactions between warfarin and smoking are inconclusive. This study aimed to systematically review all relevant clinical evidence of this interaction. Methods: We performed a systematic search using computerized databases, including PubMed, Embase, Cochrane Central Register of Controlled Trials, CINAHL, Allied and Complementary Medicine, PsycINFO, International Pharmaceutical Abstracts, and ClinicalTrials.gov from 1966 to December 2008. Keywords included "warfarin" with "smoking," "tobacco," "cigarette," and "polycyclic aromatic hydrocarbons." Original articles reporting interaction between warfarin and smoking were included. All articles were reviewed independently by two investigators for study design, population, outcomes, and quality of evidence. Results: Of the 1,240 studies retrieved, one experimental pharmacokinetic study and 12 crosssectional studies were included. The pooled analyses of multivariate studies suggested that smoking was associated with a 12.1 3% (95% CI, 6.999-17.265; P < .001) increase in warfarin dosage requirement and an additional 2.26 mg (95% CI, 2.529-7.042; P=5.355) per week compared with nonsmoking. Additional sensitivity analysis of four multivariate studies with adjustment for pharmacogenomic factors suggested that smoking was associated with a 13.21% (95% CI, 8.59%-17.83%; P < .001) increase in warfarin dosage requirement compared with nonsmokers. Results of an experimental pharmacokinetic study lend theoretical support to the findings. Conclusions: Evidence suggests that smoking may potentially cause significant interaction with warfarin by increasing warfarin clearance, which leads to reduced warfarin effects. Close monitoring of warfarin therapy should be instituted when there is a change in smoking status of patients requiring warfarin therapy. © 2011 American College of Chest Physicians.